A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants

202434 citationsJournal Articlehybrid Open Access

Authors

Shabir A. Madhi · South African Medical Research Council

Eric A. F. Simões · Colorado School of Public Health

Armando Acevedo · Clinical Research Associates

Jose M Novoa Pizarro · Hospital Padre Hurtado

Julie S. Shepard · Dayton Clinical Oncology Program

Radha Railkar · Merck & Co., Inc., Rahway, NJ, USA (United States)

Xin Cao

Abstract

Clesrovimab was generally well tolerated and exhibited an extended half-life compared to typical IgG1 antibodies, supporting its ongoing development in late-stage trials. Clinical Trial Registration. NCT03524118.

Topics & Keywords

Respiratory viral infections research Neonatal Respiratory Health Research Pneumonia and Respiratory Infections

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Infectious Diseases

Volume 231, Issue 3, pp. e478-e487

DOI: 10.1093/infdis/jiae581

Field-Weighted Citation Impact: 13.02